Immuron reported HY26 revenue from ordinary activities of AUD 4.2 million, up 4.8%, and a loss after tax attributable to shareholders of AUD 1.9 million, down 22.9%, for the six months ended 31 December 2025. Net tangible assets were 3.94 cents per share at 31 December 2025. The company ended the half with cash and cash equivalents of AUD 10.0 million and net assets of AUD 13.1 million. Operationally, Immuron highlighted record HY26 sales of AUD 4.2 million (+5.0%), including Travelan sales growth in Australia to AUD 3.2 million (+11.0%) and in the US to AUD 0.9 million (+17.0%), while Canada Travelan sales declined to AUD 0.1 million. Key updates included FDA approval of the IMM-529 investigational new drug application for a Phase 2 trial in Clostridioides difficile infection, a new US Department of Defense award to develop oral therapeutics targeting Campylobacter and Shigella, release of topline data from a Uniformed Services University trial of a third-party manufactured IMM-124E product, and the launch of ProIBS in Australia.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-021951), on March 02, 2026, and is solely responsible for the information contained therein.